<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leflunomide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leflunomide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Leflunomide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10097" href="/d/html/10097.html" rel="external">see "Leflunomide: Drug information"</a> and <a class="drug drug_patient" data-topicid="10793" href="/d/html/10793.html" rel="external">see "Leflunomide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709008"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryofetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Leflunomide is contraindicated in pregnant women because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals administered leflunomide at doses lower than the human exposure level. Exclude pregnancy before the start of treatment with leflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during leflunomide treatment and during an accelerated elimination procedure after leflunomide treatment. Stop leflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Concomitant use of leflunomide with other potentially hepatotoxic drugs may increase the risk of liver injury. Patients with preexisting acute or chronic liver disease, or those with serum ALT &gt;2 times ULN before initiating treatment, are at increased risk and should not be treated with leflunomide. Monitor ALT levels at least monthly for 6 months after starting leflunomide, and thereafter every 6 to 8 weeks. If leflunomide-induced liver injury is suspected, stop leflunomide treatment, start an accelerated drug elimination procedure, and monitor liver tests weekly until normalized.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187136"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Arava</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867333"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Leflunomide;</li>
<li>APO-Leflunomide;</li>
<li>Arava;</li>
<li>SANDOZ Leflunomide;</li>
<li>TEVA-Leflunomide</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1021385"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antirheumatic, Disease Modifying</span></li></ul></div>
<div class="block dop drugH1Div" id="F26595485"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (alternative agent): </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24334641','lexi-content-ref-31327053','lexi-content-ref-20472925','lexi-content-ref-15843668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24334641','lexi-content-ref-31327053','lexi-content-ref-20472925','lexi-content-ref-15843668'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;20 kg: Oral: 10 mg every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to 40 kg: Oral: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Oral: 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> While loading doses of 100 mg/dose were used in early clinical trials, they may be associated with toxicity; more recent studies omit the loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Silverman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Silverman.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117819"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51117820"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosage adjustment or avoidance suggested for baseline liver impairment or development of toxicity during therapy; use is contraindicated in severe hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F187140"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10097" href="/d/html/10097.html" rel="external">see "Leflunomide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1461f81-b164-46ed-a1d0-d8f2f6a93931">BK virus, in kidney transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>BK virus (viremia or nephropathy), in kidney transplant recipients (off-label use; based on limited data): Oral:</b> Loading dose: 100 mg/day for 5 days; Maintenance: 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859620','lexi-content-ref-27047808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859620','lexi-content-ref-27047808'])">Ref</a></span>) <b>or</b> Loading dose: 60 mg/day for 2 days; Maintenance: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28405598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28405598'])">Ref</a></span>); consider adjusting dose based on active metabolite serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859620','lexi-content-ref-28405598','lexi-content-ref-27047808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859620','lexi-content-ref-28405598','lexi-content-ref-27047808'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="872e8e84-073c-4d90-96b4-2eaa1d24fe9a">Cytomegalovirus disease, in transplant recipients resistant to standard antivirals, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus disease, in transplant recipients resistant to standard antivirals, adjunctive therapy (off-label use; based on limited data):</b>
<b>Oral:</b> 100 mg once daily for 3 to 5 days, followed by 20 to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20683281','lexi-content-ref-26000278','lexi-content-ref-31054984','lexi-content-ref-29226391','lexi-content-ref-30170516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20683281','lexi-content-ref-26000278','lexi-content-ref-31054984','lexi-content-ref-29226391','lexi-content-ref-30170516'])">Ref</a></span>); consider adjusting dose based on active metabolite serum concentrations and/or adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20683281','lexi-content-ref-30170516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20683281','lexi-content-ref-30170516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an alternative to methotrexate in disease-modifying antirheumatic drug–naive patients with moderate to high disease activity, or as adjunctive therapy in patients whose treatment targets have not been met despite maximally tolerated methotrexate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387','lexi-content-ref-31969328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387','lexi-content-ref-31969328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose (optional): <b>Oral:</b> 100 mg once daily for 3 days. <b>Note:</b> Loading dose may be omitted to reduce the risk of adverse effects (eg, diarrhea), particularly in patients at increased risk of hepatic or hematologic toxicity (eg, recent concomitant methotrexate or other immunosuppressive agents); onset of action may be delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15657072','lexi-content-ref-12535423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15657072','lexi-content-ref-12535423'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: <b>Oral:</b> 20 mg once daily; may reduce maintenance dose to 10 mg once daily if needed based on tolerability (maximum: 20 mg once daily). <b></b></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991853"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetics of leflunomide in kidney impairment have not been well characterized. After a single dose of 100 mg, half-life of teriflunomide (active metabolite) was similar in 3 patients on peritoneal dialysis and reduced in hemodialysis patients compared to healthy volunteers. However, the percent unbound in dialysis patients (1.51%) was higher compared to healthy volunteers (0.62%), suggesting that caution and vigilance are warranted in patients with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11884931','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11884931','lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11816264','lexi-content-ref-23179005','lexi-content-ref-16234193','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11816264','lexi-content-ref-23179005','lexi-content-ref-16234193','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11816264','lexi-content-ref-23179005','lexi-content-ref-16234193','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11816264','lexi-content-ref-23179005','lexi-content-ref-16234193','lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23447478','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23447478','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23447478','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23447478','lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> There are no specific dosage adjustments recommended (has not been studied); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>There are no specific dosage adjustments recommended (has not been studied); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989148"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic function impairment at baseline: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> Not recommended for use in patients with preexisting liver disease or those with baseline ALT &gt;2 times ULN; monitor liver function closely. Use is contraindicated in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> ALT elevations &gt;3 times ULN: Discontinue drug therapy and investigate probable cause; if leflunomide-induced, initiate accelerated drug elimination process and monitor liver tests weekly until normalized.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ALT elevations 2 to 3 times ULN: May reduce maintenance dose to 10 mg once daily; monitor ALT weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Persistent ALT elevations &gt;2 times ULN or ALT elevations &gt;3 times ULN: Discontinue treatment and initiate drug elimination procedures.</p></div>
<div class="block arsc drugH1Div" id="F57435790"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe cutaneous adverse reactions (SCARs) have been reported, including <b>Stevens-Johnson syndrome </b>(SJS), <b>toxic epidermal necrolysis </b>(TEN), and <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28138822','lexi-content-ref-18805724','lexi-content-ref-18330828','lexi-content-ref-23271613','lexi-content-ref-33629602','lexi-content-ref-16880575','lexi-content-ref-17076730','lexi-content-ref-22679188','lexi-content-ref-30720701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28138822','lexi-content-ref-18805724','lexi-content-ref-18330828','lexi-content-ref-23271613','lexi-content-ref-33629602','lexi-content-ref-16880575','lexi-content-ref-17076730','lexi-content-ref-22679188','lexi-content-ref-30720701'])">Ref</a></span>). In patients with DRESS, diarrhea is a prominent symptom indicating digestive tract involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28138822','lexi-content-ref-21410659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28138822','lexi-content-ref-21410659'])">Ref</a></span>). Other reported cutaneous reactions include <b>subacute cutaneous lupus erythematosus </b>(SCLE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15187208','lexi-content-ref-15757964','lexi-content-ref-15115526','lexi-content-ref-18413415','lexi-content-ref-27891379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15187208','lexi-content-ref-15757964','lexi-content-ref-15115526','lexi-content-ref-18413415','lexi-content-ref-27891379'])">Ref</a></span>), <b>dermal ulcer</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19538387','lexi-content-ref-12022903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19538387','lexi-content-ref-12022903'])">Ref</a></span>), <b>erythema multiforme</b>-like drug eruption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14657632','lexi-content-ref-32255229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14657632','lexi-content-ref-32255229'])">Ref</a></span>), <b>lichenoid eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28543792','lexi-content-ref-15118375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28543792','lexi-content-ref-15118375'])">Ref</a></span>), <b>keratoacanthoma</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24010514','lexi-content-ref-26352135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24010514','lexi-content-ref-26352135'])">Ref</a></span>), and <b>alopecia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31044385','lexi-content-ref-24770511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31044385','lexi-content-ref-24770511'])">Ref</a></span>). Cases of alopecia areata are often reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31044385','lexi-content-ref-22301842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31044385','lexi-content-ref-22301842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: SCARs: Non–dose-related; immunologic. SCARs, including SJS/TEN and DRESS, are T-cell–mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>). SCLE: Non–dose-related; mechanism unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; SCARs, including SJS/TEN and DRESS, usually develop 1 to 8 weeks after initiation, with cases of SJS/TEN first presenting with symptoms 11 to 14 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-21410659','lexi-content-ref-18805724','lexi-content-ref-NICE.2014','lexi-content-ref-16880575','lexi-content-ref-30720701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-21410659','lexi-content-ref-18805724','lexi-content-ref-NICE.2014','lexi-content-ref-16880575','lexi-content-ref-30720701'])">Ref</a></span>). SCLE may develop 6 weeks to several years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16197407','lexi-content-ref-15757964','lexi-content-ref-27891379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16197407','lexi-content-ref-15757964','lexi-content-ref-27891379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Certain genetic polymorphisms, although data are inconclusive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28138822','lexi-content-ref-18496682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28138822','lexi-content-ref-18496682'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Diarrhea</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate <b>diarrhea</b> is commonly reported early in therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15189743','lexi-content-ref-10628065','lexi-content-ref-9929017','lexi-content-ref-10573044','lexi-content-ref-15170904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15189743','lexi-content-ref-10628065','lexi-content-ref-9929017','lexi-content-ref-10573044','lexi-content-ref-15170904'])">Ref</a></span>). Discontinuation for diarrhea occurred in &lt;5% of patients in clinical studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10628065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10628065'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Early-onset diarrhea: May be related to effects of leflunomide on the cell cycle of gastrointestinal epithelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15170904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15170904'])">Ref</a></span>). Late-onset diarrhea: Mechanism unknown; late onset diarrhea with weight loss and abdominal pain may be related to development of inflammatory colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32942118','lexi-content-ref-32371112','lexi-content-ref-34076521','lexi-content-ref-33866790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32942118','lexi-content-ref-32371112','lexi-content-ref-34076521','lexi-content-ref-33866790'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; Early-onset diarrhea: Within first 3 months of initiation; may be transient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15170904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15170904'])">Ref</a></span>). Delayed-onset diarrhea (inflammatory or collagenous colitis): Typically after 18 to 24 months of therapy but may occur earlier or later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32942118','lexi-content-ref-32371112','lexi-content-ref-34076521','lexi-content-ref-33866790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32942118','lexi-content-ref-32371112','lexi-content-ref-34076521','lexi-content-ref-33866790'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27747512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27747512'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancytopenia</b>, <b>agranulocytosis</b>, and <b>thrombocytopenia</b> have been reported with leflunomide monotherapy and occurs more frequently in patients receiving concurrent therapy with methotrexate or other immunosuppressive agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15187208','lexi-content-ref-15189743','lexi-content-ref-16634119','lexi-content-ref-28405135','lexi-content-ref-34267852','lexi-content-ref-17929140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15187208','lexi-content-ref-15189743','lexi-content-ref-16634119','lexi-content-ref-28405135','lexi-content-ref-34267852','lexi-content-ref-17929140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; more common in first 12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33725120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33725120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16634119','lexi-content-ref-28405135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16634119','lexi-content-ref-28405135'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Leflunomide may cause <b>abnormal hepatic function tests </b>(ie, <b>increased serum alanine aminotransferase</b> and <b>increased serum aspartate aminotransferase</b>) in ~15% of patients, which are typically asymptomatic and mild (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19147616','lexi-content-ref-15189743','lexi-content-ref-15234643','lexi-content-ref-15061688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19147616','lexi-content-ref-15189743','lexi-content-ref-15234643','lexi-content-ref-15061688'])">Ref</a></span>). Severe <b>hepatic injury</b>, including fatal <b>hepatic failure</b>, has rarely been reported. The pattern of injury ranges from cholestatic to hepatocellular (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234643','lexi-content-ref-15061688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234643','lexi-content-ref-15061688'])">Ref</a></span>). <b>Hepatotoxicity</b> may result in discontinuation, upon which cases typically begin to resolve within 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33571819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33571819'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; exact mechanism unknown, although several mechanisms have been proposed, including oxidative stress (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19356086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19356086'])">Ref</a></span>), mitochondrial dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16120318','lexi-content-ref-29427785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16120318','lexi-content-ref-29427785'])">Ref</a></span>), metabolic idiosyncrasy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19605743','lexi-content-ref-25664505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19605743','lexi-content-ref-25664505'])">Ref</a></span>), and activation of the toll-like receptor-4 mediated NFκB pathway (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31476305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31476305'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; within the first 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15061688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15061688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose &gt;20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33571819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33571819'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent hepatotoxic medications</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19147616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19147616'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting acute or chronic liver disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Psoriatic arthritis versus rheumatoid arthritis indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19147616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19147616'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Leflunomide may increase susceptibility to infection, including <b>opportunistic infection</b> (especially <b>pneumonia due to <i>Pneumocystis jirovecii</i></b>, <b>tuberculosis</b> [including extrapulmonary tuberculosis], and <b>aspergillosis</b>). <b>Severe infections</b>, including <b>sepsis</b> (may be fatal) have been reported. Risk of severe infection requiring hospitalization in rheumatoid arthritis (RA) patients was ~8% in a retrospective review (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22791271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22791271'])">Ref</a></span>). In contrast, a meta-analysis found no association with a higher risk of infection versus placebo or comparator treatments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26980577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26980577'])">Ref</a></span>). Another study reported no difference in incidence of local infection in patients receiving leflunomide versus similar patients not receiving leflunomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17041441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17041441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Leflunomide reduces production of activated CD4 T cells, potentially interfering with response to infectious agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19014871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19014871'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22791271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22791271'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22791271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22791271'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent corticosteroid at higher doses (ie, prednisone ≥7.5 mg or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17937473','lexi-content-ref-22791271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17937473','lexi-content-ref-22791271'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17937473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17937473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe RA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17937473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17937473'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Interstitial lung disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial pulmonary disease</b> (ILD) and worsening of preexisting interstitial pulmonary disease have been reported including some fatalities. Bilateral ground glass opacities and diffuse alveolar damage are the most common radiologic and histopathologic findings, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24284289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24284289'])">Ref</a></span>). ILD is also associated with rheumatoid arthritis (RA) and drugs used to treat RA, such as methotrexate; therefore, causal association is unclear. A meta-analysis and two other reviews found no association with a higher risk of ILD versus placebo or comparator treatments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26980577','lexi-content-ref-24231065','lexi-content-ref-16645972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26980577','lexi-content-ref-24231065','lexi-content-ref-16645972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; typically within 3 to 5 months of initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24284289','lexi-content-ref-24231065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24284289','lexi-content-ref-24231065'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting ILD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21410426','lexi-content-ref-24284289','lexi-content-ref-19321513','lexi-content-ref-16645972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21410426','lexi-content-ref-24284289','lexi-content-ref-19321513','lexi-content-ref-16645972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of methotrexate use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16645972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16645972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cigarette smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19321513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19321513'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (&lt;40 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19321513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19321513'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Numerous cases of <b>sensorimotor neuropathy</b> and sometimes painful <b>peripheral neuropathy</b> have been reported; most patients slowly recover after treatment discontinuation, but symptoms may persist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15179412','lexi-content-ref-19080756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15179412','lexi-content-ref-19080756'])">Ref</a></span>). In one study in rheumatoid arthritis patients, new-onset and worsening of preexisting neuropathy were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16845649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16845649'])">Ref</a></span>). Quantitative sensory testing has detected peripheral nerve injury more often in leflunomide patients than in matched controls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22639744','lexi-content-ref-17229252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22639744','lexi-content-ref-17229252'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; nerve biopsies have demonstrated epineural perivascular inflammation affecting large and small myelinated nerve fibers, suggesting axonopathy with features of vasculitis. Other studies have reported nonspecific axonal loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19080756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19080756'])">Ref</a></span>). Presentation and electrodiagnostic findings suggest direct neurotoxicity, but the site of primary nerve injury is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15179412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15179412'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; often after 3 to 6 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17229252','lexi-content-ref-19080756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17229252','lexi-content-ref-19080756'])">Ref</a></span>); however, a wide range (3 days to ~3 years) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15179412','lexi-content-ref-16845649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15179412','lexi-content-ref-16845649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (&gt;60 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15179412','lexi-content-ref-16845649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15179412','lexi-content-ref-16845649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16845649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16845649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent neurotoxic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16845649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16845649'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F187106"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (9% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Alopecia table link" class="lexi-table-link" data-table-id="lexi-content-alopecia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-alopecia')">table 1</a>)</span><span class="table-link" style="display:none;">Alopecia</span>, skin rash (11% to 12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Alopecia" frame="border" id="lexi-content-alopecia" rules="all">
<caption style="text-align:center;">
<b>Leflunomide: Adverse Reaction: Alopecia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">498</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (22% to 27%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 2</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (13%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Leflunomide: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">498</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous System: Headache (10% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (9% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤8%), gastrointestinal pain (≤8%), oral mucosa ulcer (3% to 5%), vomiting (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (6% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal Hepatic Function Tests table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-hepatic-function-tests" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-hepatic-function-tests')">table 3</a>)</span><span class="table-link" style="display:none;">Abnormal Hepatic Function Tests</span>, increased serum alanine aminotransferase (&gt;3 × ULN: 2% to 4%; reversible)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-alanine-aminotransferase')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Serum Alanine Aminotransferase</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal Hepatic Function Tests" frame="border" id="lexi-content-abnormal-hepatic-function-tests" rules="all">
<caption style="text-align:center;">
<b>Leflunomide: Adverse Reaction: Abnormal Hepatic Function Tests</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">315</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">498</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Leflunomide: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Leflunomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sulfasalazine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">118</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;3 × ULN</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">498</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;3 × ULN</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">92</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;3 × ULN</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (3% to 6%), dizziness (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (6% to 8%), tenosynovitis (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (5% to 8%), rhinitis (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, leg thrombophlebitis, palpitations, varicose veins</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, enlargement of salivary glands, flatulence, sore throat, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia, increased gamma-glutamyl transferase, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, eye disease, papilledema, retinal hemorrhage, retinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, flu-like symptoms</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Necrotizing angiitis (cutaneous), vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (Yoo 2013), cutaneous lupus erythematosus, dermal ulcer (Di Nuzzo 2009), erythema multiforme (Fischer 2003), erythroderma (Shastri 2006), exacerbation of psoriasis, lichenoid eruption (May 2017), pustular psoriasis, Stevens-Johnson syndrome, toxic epidermal necrolysis (Wang 2021), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis, colitis (including microscopic colitis), oral candidiasis (Yoo 2013), pancreatitis (Cannon 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Qu 2017), keratoacanthoma (Tidwell 2016), leukopenia, neutropenia, pancytopenia (McEwan 2007), thrombocytopenia (Shields 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (van Roon 2004), hepatic injury (acute) (van Roon 2004), hepatic necrosis (acute), hepatitis, hepatoxicity (van Roon 2004), increased serum aspartate aminotransferase (van Roon 2004), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms (Adwan 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Aspergillosis (Yoo 2013), herpes zoster infection (disseminated) (Yoo 2013), opportunistic infection (Yoo 2013), sepsis (Yoo 2013), severe infection (Yoo 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy (Bonnel 2004), sensorimotor neuropathy (Bonnel 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Subacute cutaneous lupus erythematosus (Chan 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Pyelonephritis (Yoo 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease (Raj 2013), interstitial pneumonitis, pneumonia (Yoo 2013), pneumonia due to <i>Pneumocystis jirovecii </i>(Yoo 2013), pulmonary cryptococcosis (Yoo 2013), pulmonary fibrosis, pulmonary hypertension (Collini 2022), tonsillitis (Yoo 2013), tuberculosis (Yoo 2013)</p></div>
<div class="block coi drugH1Div" id="F187118"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity (including anaphylaxis) to leflunomide or any component of the formulation; severe hepatic impairment; concomitant treatment with teriflunomide; pregnant females.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to teriflunomide; moderate to severe renal impairment; immunodeficiency states; impaired bone marrow function or significant anemia, leukopenia, neutropenia, or thrombocytopenia due to causes other than rheumatoid arthritis; serious infections; impaired liver function; severe hypoproteinemia; females of reproductive potential who are not using reliable contraception before, during, and for a period of 2 years after treatment with leflunomide (or as long as plasma levels of the active metabolite are above 0.02 mg/L); breastfeeding; patients &lt;18 years of age.</p></div>
<div class="block war drugH1Div" id="F187103"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Use of some immunosuppressive medications may increase the risk of malignancies, especially lymphoproliferative disorders; impact of leflunomide on the development and course of malignancies is not fully defined.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunodeficiency or infection: Use caution in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with chronic, latent, or localized infections. Use is not recommended in patients with severe immunodeficiency or severe, uncontrolled infections. Patients should be screened for tuberculosis (TB) (disease [active TB] and infection [latent TB]) and if necessary, treated prior to initiating leflunomide therapy. Safety has not been established in patients with TB infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: No clinical data are available on the efficacy and safety of vaccinations during leflunomide treatment. Vaccination with live vaccines is not recommended; consider the long elimination half-life of the leflunomide active metabolite (eg, teriflunomide) when considering live vaccine administration after leflunomide discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug elimination procedure: Due to slow elimination and variations in clearance, it may take up to 2 years to reach low levels of leflunomide metabolite (eg, teriflunomide) serum concentrations. An accelerated drug elimination procedure using cholestyramine or activated charcoal is recommended when a more rapid elimination is needed. Initiate accelerated elimination procedures in patients when a severe adverse reaction occurs (eg, severe dermatologic reaction, suspected liver injury, bone marrow suppression, serious infection, interstitial lung disease, peripheral neuropathy, suspected hypersensitivity) or if pregnancy occurs during treatment. Refer to the manufacturer's labeling for detailed accelerated elimination procedure. Verify plasma teriflunomide concentrations are &lt;0.02 mg/L by tests at least 14 days apart. If concentrations are &gt;0.02 mg/L, repeat the accelerated elimination procedure. Use of accelerated drug elimination may potentially result in return of disease activity if the patient has been responding to leflunomide treatment.</p></div>
<div class="block foc drugH1Div" id="F187114"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arava: 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F187099"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F187120"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Arava Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $59.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $59.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Leflunomide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $16.41 - $16.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $6.00 - $16.42</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867334"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arava: 10 mg, 20 mg, 100 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block admp drugH1Div" id="F52613133"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p></div>
<div class="block adm drugH1Div" id="F9525956"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer without regard to meals.</p></div>
<div class="block hazard drugH1Div" id="F49104525"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F187131"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53567483"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of active rheumatoid arthritis (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F16330214"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Leflunomide may be confused with lenalidomide</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F187157"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2; <b>Inhibits</b> BCRP/ABCG2, CYP2C8 (moderate), OAT1/3, OATP1B1/1B3 (SLCO1B1/1B3); <b>Induces</b> CYP1A2 (moderate)</p></div>
<div class="block dri drugH1Div" id="F187108"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Alpelisib.  Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inducers (Moderate) may decrease the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Atogepant.  Management: For episodic migraine, the recommended atogepant dose is 10 mg or 30 mg once daily if given with OATP1B1/1B3 inhibitors. For chronic migraine, the recommended atogepant dose is 30 mg once daily with OATP1B1/1B3 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Leflunomide may increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.  Management: Consider alternatives to moderate CYP1A2 inducers during therapy with bendamustine due to the potential for decreased bendamustine plasma concentrations and reduced efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: BCRP/ABCG2 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with BCRP inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease serum concentrations of the active metabolite(s) of Leflunomide. Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Brincidofovir.  Management: Consider alternatives to OATP1B/1B3 inhibitors in patients treated with brincidofovir. If coadministration is required, administer OATP1B1/1B3 inhibitors at least 3 hours after brincidofovir and increase monitoring for brincidofovir adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May decrease serum concentrations of the active metabolite(s) of Leflunomide. Specifically, concentrations of teriflunomide may decrease. Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to charcoal whenever possible. Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inducers (Moderate) may decrease the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Leflunomide may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding leflunomide for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Daprodustat.  Management: Reduce the daprodustat starting dose by half if combined with moderate CYP2C8 inhibitors, unless the dose is 1 mg, then no dose adjustment is required. Monitor hemoglobin and adjust daprodustat dose when starting or stopping moderate CYP2C8 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Dasabuvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desloratadine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Desloratadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Elagolix. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Elagolix, Estradiol, and Norethindrone. Specifically, concentrations of elagolix may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with OATP1B1/1B3 inhibitors and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Enzalutamide. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Erlotinib.  Management: Avoid the concomitant use of erlotinib and moderate CYP1A2 inducers if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP1A2 Inducers (Moderate) may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of Leflunomide. Specifically, the risks of hepatoxicity and hematologic toxicity may be increased. Management: If leflunomide is coadministered with methotrexate, initiate leflunomide 20 mg once daily without use of a loading dose. Monitor for methotrexate-induced hepatic toxicity frequently (see monograph for details) and monitor blood counts monthly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OAT1/3 Substrates (Clinically Relevant): Leflunomide may increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors): Leflunomide may increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Specifically, the concentrations of the dasabuvir component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Pirfenidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase serum concentrations of the active metabolite(s) of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May increase serum concentrations of the active metabolite(s) of Leflunomide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riluzole: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Riluzole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inducers (Moderate) may decrease the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Leflunomide may increase the serum concentration of Rosuvastatin.  Management: Limit the maximum adult rosuvastatin dose to 10 mg/day in patients receiving leflunomide, and monitor for evidence of rosuvastatin toxicity (eg, muscle toxicity, elevated transaminase concentrations).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag.  Management: Reduce the selexipag dose to once daily when combined with moderate CYP2C8 inhibitors. Revert back to twice daily selexipag dosing upon stopping the moderate CYP2C8 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: Leflunomide may enhance the adverse/toxic effect of Teriflunomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inducers (Moderate) may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inducers (Moderate) may decrease the serum concentration of TiZANidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Leflunomide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: Leflunomide may increase the serum concentration of TOLBUTamide. Specifically, the active metabolite of leflunomide (teriflunomide) may both increase total tolbutamide concentrations and increase the free fraction (i.e., non-protein bound) of tolbutamide. TOLBUTamide may increase the serum concentration of Leflunomide. Specifically, tolbutamide may increase the proportion of non-protein-bound (i.e., free fraction) teriflunomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treprostinil: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Treprostinil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: BCRP/ABCG2 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a BCRP inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Leflunomide may enhance the anticoagulant effect of Warfarin. Leflunomide may diminish the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F187132"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">No interactions with food have been noted.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307977"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: </b>
<b>Exclude pregnancy before the start of treatment with leflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during leflunomide treatment and during an accelerated elimination procedure after leflunomide treatment. </b></p>
<p style="text-indent:0em;margin-top:2em;">Females of reproductive potential should not receive therapy until pregnancy has been excluded, they have been counseled concerning fetal risk, and reliable contraceptive measures have been confirmed. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) are verified. This may be accomplished by the use of an enhanced drug elimination procedure using cholestyramine. Serum concentrations &lt;0.02 mg/L should be verified by 2 separate tests performed at least 14 days apart. If serum concentrations are &gt;0.02 mg/L, additional cholestyramine treatment should be considered. Use of the accelerated elimination procedure is recommended in all females of reproductive potential upon discontinuation of leflunomide. Without the use of the accelerated elimination procedure, it can take up to 2 years to reach undetectable plasma concentrations.</p>
<p style="text-indent:0em;margin-top:2em;">Use of leflunomide may be considered for males with rheumatic and musculoskeletal diseases who are planning to father a child (recommendation based on limited human data) (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F187121"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: </b>
<b>Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level. Exclude pregnancy before the start of treatment with leflunomide in females of reproductive potential. Stop leflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant.</b></p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following in utero fetal exposure to leflunomide is limited (Bérard 2018; Cassina 2012; Chambers 2010; Henson 2020; Pfaller 2020; Weber-Schoendorfer 2017). Based on available data, no consistent pattern of congenital abnormalities has been observed (Henson 2020; Pfaller 2020). The accelerated elimination procedure may decrease potential risks to the fetus by decreasing the plasma concentration teriflunomide, of the active metabolite of leflunomide. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) are verified.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to leflunomide is ongoing. Health care providers are encouraged to enroll women exposed to leflunomide during pregnancy in the Pregnancy Registry (1-877-311-8972 or http://www.pregnancystudies.org/participate-ina-study/).</p></div>
<div class="block mopp drugH1Div" id="F53567473"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline: Pregnancy test (in patients who can become pregnant); active and latent tuberculosis screening; blood pressure, CBC, serum transaminases.</p>
<p style="text-indent:-2em;margin-left:2em;">During therapy: CBC (WBC, hemoglobin, hematocrit, and platelet count) and serum transaminases monthly for 6 months; if stable, can decrease monitoring frequency to every 6 to 8 weeks; continue monthly CBC monitoring in patients receiving other immunosuppressants. Monitor blood pressure, signs/symptoms of severe infection, and symptoms of hepatotoxicity.</p></div>
<div class="block pha drugH1Div" id="F187102"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Leflunomide is an immunomodulatory agent that inhibits pyrimidine synthesis, resulting in antiproliferative and anti-inflammatory effects. Leflunomide is a prodrug; the active metabolite is responsible for activity. For CMV, may interfere with virion assembly. </p></div>
<div class="block phk drugH1Div" id="F187117"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Teriflunomide: 11 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Teriflunomide: &gt;99% to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to an active metabolite teriflunomide, which accounts for nearly all pharmacologic activity; further metabolism to multiple inactive metabolites; undergoes enterohepatic recirculation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Teriflunomide: Mean: 18 to 19 days; enterohepatic recycling appears to contribute to the long half-life of this agent, since activated charcoal and cholestyramine substantially reduce plasma half-life </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Teriflunomide: 6 to 12 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (37.5%); urine (22.6%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187124"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-leflunomide | Arava</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Afiancen | Apo leflunomida | Arava | Filartros | Fludart | Fluxap | Inmunoartro | Lefluar | Leflulep | Leflunomida sc</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid medac | Leflunomid Stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-leflunomide | Arabloc | Arava | Ataris | Leflunomide an | Leflunomide ga | Leflunomide gh | Leflunomide sandoz | Lunava</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arolef | Dimar | Leflu | Lera | Nodia</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide ab | Leflunomide apotex | Leflunomide jenson | Leflunomide Mylan | Leflunomide sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide Teva</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomida | Lfm leflunomida | Reumian</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid Gebro | Leflunomid Mepha | Leflunomid sandoz | Leflunomid spirig hc | Leflunomide Zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Arava | Artrotin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai ruo hua | Guan ping | He pai | Tuo shu | Ya bang sang ke | You tong</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Arava | Immunex | Leflava | Leflunex | Leflunomida | Lefluvitae | Lerada | Zoratomin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflon | Leflugen | Leflunomid Apotex | Leflunomid sandoz | Leflunomide medac | Leflunopharm | Repso</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflon | Leflunomid | Leflunomid 1 A Pharma | Leflunomid al | Leflunomid Aristo | Leflunomid bluefish | Leflunomid CT | Leflunomid heumann | Leflunomid hexal | Leflunomid medac | Leflunomid Ratiopharm | Leflunomid Stada | Leflunomid tillomed | Leflunomid Winthrop | Leflunomid Zentiva | Leflunomide medac</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide sandoz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apetoid | Arthfree | Avara | Leflumine | Rafix | Vamid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arava | Lefluartil | Leflunomida Apotex | Leflunomida cinfa | Leflunomida Medac | Leflunomida mylan | Leflunomida Normon | Leflunomida Ratiopharm | Leflunomida stada | Leflunomida tecnigen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide medac | Leflunomide ratiopharm | Leflunomide stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide biogaran | Leflunomide eg | Leflunomide Mylan | Leflunomide ratiopharm | Leflunomide winthrop</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide Mylan | Leflunomide tillomed</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Arava | Lefid | Lefluonia</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Alfimid | Arava</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid Apotex | Leflunomid sandoz | Leflunomide Mylan | Repso</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide medac</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Arava | Cleft | Fluna | Lefday | Leflar | Lefno | Lefra | Lefsum | Leftab | Lefumide | Lefumod | Lefutoid | Leorch | Lisifen | Lunamide | O left | Rhulef | Rumalef</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide Mylan | Leflunomide sandoz | Leflunomide tecnigen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Arava | Arotan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Arotan | Lefra | Lefumide | Lunomide</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alvogen leflunomide | Arava | Arey | Aris | Burova | Duroba | Durova | Kimara | Lefilo | Lefl | Leflu | Lefmid | Lefru | Lefva | Leluba | Lenava | Lualba | Myungmoon leflunomide | R a | Rheumakin | Rheumide</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Arava | Arotan | Arthfree</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid sandoz | Leflunomide sandoz</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid sandoz | Leflunomide sandoz</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Almura | Arava | Avattor | Deladex | Filarin | Galdione | Iguanos | Imagine | Koralix | Leflunomida | Leflunomida corne | Lerivril | Ramtener</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide apotex | Leflunomide aurobindo | Leflunomide CF | Leflunomide Mylan | Leflunomide ratiopharm | Leflunomide sandoz | Leflunomide tillomed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomide medac | Leflunomide Zentiva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aft Leflunomide | Apo-leflunomide | Arava</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Almora | Arava | Aravida | Artroflu | Etodolo | Filartros | Flexagin | Flumidar | Leflumard | Leflumide | Leflunomida | Lemida</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aidra | Ariva | Cara | Cynova | Defumide | Dimara | Eflun | Lefanor | Lefid | Leflonid | Leflu | Lefluno | Lefodil | Lefomide | Lefora | Leforex | Lenomide | Life | Lufid | Lunamid | Movelef | Ra mide | Rhomed | Rhulef</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid bluefish | Leflunomide medac | Leflunomide sandoz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomida farmoz | Leflunomida Medac | Leflunomida pentafarma</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Arava | Artrotin | Fluxet | Imaxetil | Leflumix | Leflunomida ac | Leflunomida cipla | Leflunomida natrodale | Leflunomida prosalud | Leflux</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Arava | Arresto | Ehlafra | Leflaid | Lefomid | Ralef</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-leflunomide | Arava</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid bluefish | Leflunomide medac | Leflunomide Zentiva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflunomid medac</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflon | Leflunomid sandoz | Leflunomid Winthrop | Leflunomide medac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Arava | Lareya</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Arava</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aramid | Arava | Bageda | Lefumix | Ralef | Reumil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Arava | Arheuma | Pharnomide</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Arava | Leflutab | Lefno</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Arthfree | Lefra</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Arava | Kevadon | Kinetos | Reumine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arava | Lefra</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Arava | Lunar | Ravalef | Rheumalef</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lefra</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Lefra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.1">
<a name="HazardousDrugs.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28138822">
<a name="28138822"></a>Adwan MH. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and the rheumatologist. <i>Curr Rheumatol Rep</i>. 2017;19(1):3. doi:10.1007/s11926-017-0626-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/28138822/pubmed" id="28138822" target="_blank">28138822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33571819">
<a name="33571819"></a>Alamri RD, Elmeligy MA, Albalawi GA, Alquayr SM, Alsubhi SS, El-Ghaiesh SH. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.<i> Int Immunopharmacol</i>. 2021;93:107398. doi:10.1016/j.intimp.2021.107398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/33571819/pubmed" id="33571819" target="_blank">33571819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24334641">
<a name="24334641"></a>Alcântara AC, Leite CA, Leite AC, Sidrim JJ, Silva FS Jr, Rocha FA. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. <i>J Rheumatol</i>. 2014;41(2):338-344. doi:10.3899/jrheum.130294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/24334641/pubmed" id="24334641" target="_blank">24334641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arava.1">
<a name="Arava.1"></a>Arava (leflunomide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arava.2">
<a name="Arava.2"></a>Arava (leflunomide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arava.3">
<a name="Arava.3"></a>Arava (leflunomide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20683281">
<a name="20683281"></a>Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. <i>Transplantation.</i> 2010;90(4):419-426. doi:10.1097/TP.0b013e3181e94106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/20683281/pubmed" id="20683281" target="_blank">20683281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18594298">
<a name="18594298"></a>Avery RK. Update in Management of Ganciclovir-Resistant Cytomegalovirus Infection. <i>Curr Opin Infect Dis</i>. 2008;21(4):433-437. doi:10.1097/QCO.0b013e328307c7b4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/18594298/pubmed" id="18594298" target="_blank">18594298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31327053">
<a name="31327053"></a>Ayaz NA, Karadağ ŞG, Çakmak F, Çakan M, Tanatar A, Sönmez HE. Leflunomide treatment in juvenile idiopathic arthritis. <i>Rheumatol Int</i>. 2019;39(9):1615-1619. doi:10.1007/s00296-019-04385-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31327053/pubmed" id="31327053" target="_blank">31327053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11816264">
<a name="11816264"></a>Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. <i>Ann Pharmacother</i>. 2002;36(1):75-77. doi:10.1345/aph.1A127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/11816264/pubmed" id="11816264" target="_blank">11816264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29222350">
<a name="29222350"></a>Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. <i>Ann Rheum Dis.</i> 2018;77(4):500-509. doi:10.1136/annrheumdis-2017-212078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/29222350/pubmed" id="29222350" target="_blank">29222350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23179005">
<a name="23179005"></a>Bergner R, Peters L, Schmitt V, Löffler C. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. <i>Clin Rheumatol</i>. 2013;32(2):267-270. doi:10.1007/s10067-012-2122-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/23179005/pubmed" id="23179005" target="_blank">23179005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19605743">
<a name="19605743"></a>Bohanec Grabar P, Rozman B, Logar D, Praprotnik S, Dolzan V. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2009;68(8):1367-1368. doi:10.1136/ard.2008.099093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19605743/pubmed" id="19605743" target="_blank">19605743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18496682">
<a name="18496682"></a>Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. <i>Eur J Clin Pharmacol</i>. 2008;64(9):871-876. doi:10.1007/s00228-008-0498-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/18496682/pubmed" id="18496682" target="_blank">18496682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15179412">
<a name="15179412"></a>Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. <i>Clin Pharmacol Ther</i>. 2004;75(6):580-585. doi:10.1016/j.clpt.2004.01.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15179412/pubmed" id="15179412" target="_blank">15179412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774327">
<a name="31774327"></a>Borucki R, Werth VP. Cutaneous lupus erythematosus induced by drugs - novel insights. <i>Expert Rev Clin Pharmacol</i>. 2020;13(1):35-42. doi:10.1080/17512433.2020.1698290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31774327/pubmed" id="31774327" target="_blank">31774327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15468352">
<a name="15468352"></a>Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. <i>J Rheumatol</i>. 2004;31(10):1906-1911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15468352/pubmed" id="15468352" target="_blank">15468352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19014871">
<a name="19014871"></a>Caporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C. DMARDS and infections in rheumatoid arthritis. <i>Autoimmun Rev</i>. 2008;8(2):139-143. doi:10.1016/j.autrev.2008.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19014871/pubmed" id="19014871" target="_blank">19014871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22307734">
<a name="22307734"></a>Cassina M, Johnson DL, Robinson LK, et al; Organization of Teratology Information Specialists Collaborative Research Group. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. <i>Arthritis Rheum</i>. 2012;64(7):2085-2094. doi:10.1002/art.34419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/22307734/pubmed" id="22307734" target="_blank">22307734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20131283">
<a name="20131283"></a>Chambers CD, Johnson DL, Robinson LK, et al; Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who have taken leflunomide during pregnancy. <i>Arthritis Rheum.</i> 2010;62(5):1494-1503. doi:10.1002/art.27358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/20131283/pubmed" id="20131283" target="_blank">20131283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16197407">
<a name="16197407"></a>Chan SK, Hazleman BL, Burrows NP. Subacute cutaneous lupus erythematosus precipitated by leflunomide. <i>Clin Exp Dermatol</i>. 2005;30(6):724-725. doi:10.1111/j.1365-2230.2005.01898.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16197407/pubmed" id="16197407" target="_blank">16197407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15187208">
<a name="15187208"></a>Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. <i>Ann Pharmacother.</i> 2004;38(7-8):1206-1211. doi:10.1345/aph.1E012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15187208/pubmed" id="15187208" target="_blank">15187208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26000278">
<a name="26000278"></a>Chon WJ, Kadambi PV, Xu C, et al. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago. <i>Case Rep Nephrol Dial.</i> 2015;5(1):96-105. doi:10.1159/000381470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/26000278/pubmed" id="26000278" target="_blank">26000278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35949584">
<a name="35949584"></a>Collini V, Driussi M, Nalli C, et al. Leflunomide-induced pulmonary arterial hypertension: Case report and review of literature. <i>J Cardiol Cases</i>. 2022;26(2):148-150. doi:10.1016/j.jccase.2022.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/35949584/pubmed" id="35949584" target="_blank">35949584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26980577">
<a name="26980577"></a>Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Leflunomide use and risk of lung disease in rheumatoid arthritis: A systematic literature review and metaanalysis of randomized controlled trials. <i>J Rheumatol</i>. 2016;43(5):855-860. doi:10.3899/jrheum.150674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/26980577/pubmed" id="26980577" target="_blank">26980577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19147616">
<a name="19147616"></a>Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. <i>Ann Rheum Dis</i>. 2010;69(1):43-47. doi:10.1136/ard.2008.101378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19147616/pubmed" id="19147616" target="_blank">19147616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19538387">
<a name="19538387"></a>Di Nuzzo S, Zanni M, De Panfilis G. Cutaneous ulceration induced by leflunomide in a psoriatic patient. <i>Int J Dermatol</i>. 2009;48(6):666-668. doi:10.1111/j.1365-4632.2009.03981.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19538387/pubmed" id="19538387" target="_blank">19538387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21410659">
<a name="21410659"></a>Do-Pham G, Charachon A, Duong TA, et al. Drug reaction with eosinophilia and systemic symptoms and severe involvement of digestive tract: description of two cases. <i>Br J Dermatol</i>. 2011;165(1):207-209. doi:10.1111/j.1365-2133.2011.10293.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/21410659/pubmed" id="21410659" target="_blank">21410659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27747512">
<a name="27747512"></a>Duquette A, Frenette AJ, Doré M. Chronic diarrhea associated with high teriflunomide blood concentration. <i>Rheumatol Ther</i>. 2016;3(1):179-185. doi:10.1007/s40744-016-0025-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/27747512/pubmed" id="27747512" target="_blank">27747512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31476305">
<a name="31476305"></a>Elshaer RE, Tawfik MK, Nosseir N, et al. Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway. <i>Life Sci</i>. 2019;235:116824. doi:10.1016/j.lfs.2019.116824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31476305/pubmed" id="31476305" target="_blank">31476305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32942118">
<a name="32942118"></a>Esfahani NZ, von Geldern G, Romba MC, Parikh DA, Wundes A. Inflammatory colitis associated with teriflunomide. <i>Mult Scler Relat Disord</i>. 2020;46:102480. doi:10.1016/j.msard.2020.102480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/32942118/pubmed" id="32942118" target="_blank">32942118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14657632">
<a name="14657632"></a>Fischer TW, Bauer HI, Graefe T, Barta U, Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. <i>Dermatology</i>. 2003;207(4):386-389. doi:10.1159/000074120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/14657632/pubmed" id="14657632" target="_blank">14657632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20472925">
<a name="20472925"></a>Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. <i>J Rheumatol</i>. 2010;37(8):1763-1767. doi:10.3899/jrheum.090874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/20472925/pubmed" id="20472925" target="_blank">20472925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24010514">
<a name="24010514"></a>Frances L, Guijarro J, Marin I, Leiva-Salinas Mdel C, Bouret AM. Multiple eruptive keratoacanthomas associated with leflunomide. <i>Dermatol Online J</i>. 2013;19(7):18968.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/24010514/pubmed" id="24010514" target="_blank">24010514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30175491">
<a name="30175491"></a>Gabardi S, Pavlakis M, Tan C, et al. New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines.<i> Transpl Infect Dis</i>. 2018;20(6):e12985. doi:10.1111/tid.12985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/30175491/pubmed" id="30175491" target="_blank">30175491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15757964">
<a name="15757964"></a>Goëb V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. <i>Rheumatology (Oxford)</i>. 2005;44(6):823-824. doi:10.1093/rheumatology/keh586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15757964/pubmed" id="15757964" target="_blank">15757964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31054984">
<a name="31054984"></a>Gokarn A, Toshniwal A, Pathak A, et al. Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant [published online May 2, 2019]. <i>Biol Blood Marrow Transplant</i>. doi:10.1016/j.bbmt.2019.04.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31054984/pubmed" id="31054984" target="_blank">31054984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18696405">
<a name="18696405"></a>Gugenberger C, Donner P, Naami A, Berges W. Persistent diarrhea and loss of weight during therapy with leflunomide [in German]. <i>Dtsch Med Wochenschr</i>. 2008;133(34-35):1730-1732. doi:10.1055/s-0028-1082795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/18696405/pubmed" id="18696405" target="_blank">18696405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20563249">
<a name="20563249"></a>Hail N Jr, Chen P, Bushman LR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. <i>Neoplasia</i>. 2010;12(6):464-475. doi:10.1593/neo.10168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/20563249/pubmed" id="20563249" target="_blank">20563249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18805724">
<a name="18805724"></a>Hassikou H, El Haouri M, Tabache F, Baaj M, Safi S, Hadri L. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. <i>Joint Bone Spine</i>. 2008;75(5):597-599. doi:10.1016/j.jbspin.2007.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/18805724/pubmed" id="18805724" target="_blank">18805724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32407881">
<a name="32407881"></a>Henson LJ, Afsar S, Davenport L, Purvis A, Poole EM, Truffinet P. Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. <i>Reprod Toxicol</i>. 2020;95:45-50. doi:10.1016/j.reprotox.2020.04.073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/32407881/pubmed" id="32407881" target="_blank">32407881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859620">
<a name="30859620"></a>Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13528. doi:10.1111/ctr.13528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/30859620/pubmed" id="30859620" target="_blank">30859620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32255229">
<a name="32255229"></a>Hu YQ, Mu ZL, Zhang JZ. Erythema multiforme-like drug eruption in a patient with systemic lupus erythematosus treated with leflunomide. <i>Dermatol Ther</i>. 2020;33(3):e13382. doi:10.1111/dth.13382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/32255229/pubmed" id="32255229" target="_blank">32255229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21410426">
<a name="21410426"></a>Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. <i>Expert Opin Drug Saf</i>. 2011;10(4):603-611. doi:10.1517/14740338.2011.560835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/21410426/pubmed" id="21410426" target="_blank">21410426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234193">
<a name="16234193"></a>Iwamoto M, Homma S, Asano Y, Minota S. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. <i>Scand J Rheumatol</i>. 2005;34(5):410-411. doi:10.1080/03009740510018723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16234193/pubmed" id="16234193" target="_blank">16234193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17937473">
<a name="17937473"></a>Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. <i>J Rheumatol</i>. 2007;34(11):2201-2203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/17937473/pubmed" id="17937473" target="_blank">17937473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18330828">
<a name="18330828"></a>Jian X, Guo G, Ruan Y, Lin D, Li X. Severe cutaneous adverse drug reaction to leflunomide: a report of two cases. <i>Cutan Ocul Toxicol</i>. 2008;27(1):5-9. doi:10.1080/15569520701662866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/18330828/pubmed" id="18330828" target="_blank">18330828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15167608">
<a name="15167608"></a>John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. <i>Transplantation.</i> 2004;77(9):1460-1461. doi:10.1097/01.tp.0000122185.64004.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15167608/pubmed" id="15167608" target="_blank">15167608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28405598">
<a name="28405598"></a>Kable K, Davies CD, O'connell PJ, Chapman JR, Nankivell BJ. Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin.<i> Transplant Direct.</i> 2017;3(4):e142. doi:10.1097/TXD.0000000000000641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/28405598/pubmed" id="28405598" target="_blank">28405598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15115526">
<a name="15115526"></a>Kerr OA, Murray CS, Tidman MJ. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol. 2004;29(3):319-320. doi:10.1111/j.1365-2230.2004.01527.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15115526/pubmed" id="15115526" target="_blank">15115526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22639744">
<a name="22639744"></a>Kim HK, Park SB, Park JW, et al. The effect of leflunomide on cold and vibratory sensation in patients with rheumatoid arthritis. <i>Ann Rehabil Med</i>. 2012;36(2):207-212. doi:10.5535/arm.2012.36.2.207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/22639744/pubmed" id="22639744" target="_blank">22639744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31044385">
<a name="31044385"></a>Koller G, Cusnir I, Hall J, Ye C. Reversible alopecia areata: a little known side effect of leflunomide. <i>Clin Rheumatol.</i> 2019;38(7):2015-2016. doi:10.1007/s10067-019-04577-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31044385/pubmed" id="31044385" target="_blank">31044385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29055483">
<a name="29055483"></a>Landais A, Alhendi R, Gouverneur A, Teron-Aboud B. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis. <i>Mult Scler Relat Disord</i>. 2017;17:92-94. doi:10.1016/j.msard.2017.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/29055483/pubmed" id="29055483" target="_blank">29055483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24770511">
<a name="24770511"></a>Lazzarini R, Capareli GC, Buense R, Lellis RF. Alopecia universalis during treatment with leflunomide and adalimumab - case report. <i>An Bras Dermatol</i>. 2014;89(2):320-322. doi:10.1590/abd1806-4841.20142944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/24770511/pubmed" id="24770511" target="_blank">24770511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30143945">
<a name="30143945"></a>Lebrun C, Rocher F. Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs. <i>CNS Drugs</i>. 2018;32(10):939-949. doi:10.1007/s40263-018-0564-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/30143945/pubmed" id="30143945" target="_blank">30143945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alembic.1">
<a name="Alembic.1"></a>Leflunomide tablet [prescribing information]. Bridgewater, NJ: Alembic Pharmaceuticals Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15189743">
<a name="15189743"></a>Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. <i>Clin Ther</i>. 2004;26(4):447-459. doi:10.1016/s0149-2918(04)90048-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15189743/pubmed" id="15189743" target="_blank">15189743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32371112">
<a name="32371112"></a>Lui J, de la Fuente J, Halland M. Colitis in a rheumatologic patient. <i>Gastroenterology</i>. 2020;159(6):2034-2035. doi:10.1053/j.gastro.2020.04.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/32371112/pubmed" id="32371112" target="_blank">32371112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15657072">
<a name="15657072"></a>Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. <i>Rheumatology (Oxford)</i>. 2005;44(3):280-286. doi:10.1093/rheumatology/keh500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15657072/pubmed" id="15657072" target="_blank">15657072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16845649">
<a name="16845649"></a>Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(1):74-78. doi:10.1002/pds.1282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16845649/pubmed" id="16845649" target="_blank">16845649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413415">
<a name="18413415"></a>Marzano AV, Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. <i>Lupus</i>. 2008;17(4):329-331. doi:10.1177/0961203307087189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/18413415/pubmed" id="18413415" target="_blank">18413415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543792">
<a name="28543792"></a>May C, Fleckman P, Brandling-Bennett HA, Cole B, Sidbury R. Lichenoid drug eruption with prominent nail changes due to leflunomide in a 12-Year-old child. <i>Pediatr Dermatol</i>. 2017;34(4):e225-e226. doi:10.1111/pde.13168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/28543792/pubmed" id="28543792" target="_blank">28543792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12022903">
<a name="12022903"></a>McCoy CM. Leflunomide-associated skin ulceration. <i>Ann Pharmacother</i>. 2002;36(6):1009-1011. doi:10.1345/aph.1A347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/12022903/pubmed" id="12022903" target="_blank">12022903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16634119">
<a name="16634119"></a>McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(1):65-73. doi:10.1002/pds.1236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16634119/pubmed" id="16634119" target="_blank">16634119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31998289">
<a name="31998289"></a>Melamed E, Lee MW. Multiple sclerosis and cancer: The ying-yang effect of disease modifying therapies. <i>Front Immunol</i>. 2020;10:2954. doi:10.3389/fimmu.2019.02954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31998289/pubmed" id="31998289" target="_blank">31998289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34076521">
<a name="34076521"></a>Muhammad T, Zafar M, Quiroga J, Whitehead M. Leflunomide-induced delayed onset colitis. <i>Br J Hosp Med (Lond)</i>. 2021;82(5):1-3. doi:10.12968/hmed.2020.0610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/34076521/pubmed" id="34076521" target="_blank">34076521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33725120">
<a name="33725120"></a>Nakafero G, Grainge MJ, Card T, et al. What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? <i>Rheumatology (Oxford)</i>. 2021;60(12):5785-5794. doi:10.1093/rheumatology/keab254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/33725120/pubmed" id="33725120" target="_blank">33725120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34718430">
<a name="34718430"></a>Nakafero G, Grainge MJ, Card T, et al. Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. <i>Rheumatology (Oxford)</i>. 2022;61(7):2783-2791. doi:10.1093/rheumatology/keab790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/34718430/pubmed" id="34718430" target="_blank">34718430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management (CG183). Clinical guideline 183. Published September 2014. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22301842">
<a name="22301842"></a>Navarro R, Daudén E, Gallo E, Santiago Sánchez-Mateos D, García-Diez A. Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature. <i>Skin Pharmacol Physiol</i>. 2012;25(2):107-110. doi:10.1159/000335264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/22301842/pubmed" id="22301842" target="_blank">22301842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27047808">
<a name="27047808"></a>Nesselhauf N, Strutt J, Bastani B. Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. <i>J Nephropathol.</i> 2016;5(1):34-37. doi:10.15171/jnp.2016.06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/27047808/pubmed" id="27047808" target="_blank">27047808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33866790">
<a name="33866790"></a>Núñez P, Quera R, Flores L, Contreras L. Leflunomide as a cause of collagenous colitis: an entity to consider. <i>Rev Esp Enferm Dig</i>. 2021;113(10):735. doi:10.17235/reed.2021.8015/2021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/33866790/pubmed" id="33866790" target="_blank">33866790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10628065">
<a name="10628065"></a>Olsen NJ, Strand V, Kremer JM. Leflunomide for the treatment of rheumatoid arthritis. <i>Bull Rheum Dis</i>. 1999;48(8):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/10628065/pubmed" id="10628065" target="_blank">10628065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12535423">
<a name="12535423"></a>Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. <i>Cochrane Database Syst Rev</i>. 2003;(1):CD002047. doi:10.1002/14651858.CD002047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/12535423/pubmed" id="12535423" target="_blank">12535423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31758422">
<a name="31758422"></a>Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S. A critical review of the reproductive safety of leflunomide. <i>Clin Rheumatol</i>. 2020;39(2):607-612. doi:10.1007/s10067-019-04819-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31758422/pubmed" id="31758422" target="_blank">31758422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23271613">
<a name="23271613"></a>Pinto B, Dhir V, Krishnan S, Nada R. Leflunomide-induced DRESS syndrome with renal involvement and vasculitis. <i>Clin Rheumatol</i>. 2013;32(5):689-693. doi:10.1007/s10067-012-2152-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/23271613/pubmed" id="23271613" target="_blank">23271613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28405135">
<a name="28405135"></a>Qu C, Lu Y, Liu W. Severe bone marrow suppression accompanying pulmonary infection and hemorrhage of the digestive tract associated with leflunomide and low-dose methotrexate combination therapy. <i>J Pharmacol Pharmacother</i>. 2017;8(1):35-37. doi:10.4103/jpp.JPP_93_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/28405135/pubmed" id="28405135" target="_blank">28405135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24284289">
<a name="24284289"></a>Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). <i>Sarcoidosis Vasc Diffuse Lung Dis</i>. 2013;30(3):167-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/24284289/pubmed" id="24284289" target="_blank">24284289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33629602">
<a name="33629602"></a>Rao S, Sunkara A, Srivastava N, Sampat P, Ramos C, Albert E. An uncommon presentation of DRESS syndrome secondary to leflunomide use: A case report. <i>J Investig Med High Impact Case Rep</i>. 2021;9:2324709621997282. doi:10.1177/2324709621997282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/33629602/pubmed" id="33629602" target="_blank">33629602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17229252">
<a name="17229252"></a>Richards BL, Spies J, McGill N, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. <i>Intern Med J</i>. 2007;37(2):101-107. doi:10.1111/j.1445-5994.2007.01266.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/17229252/pubmed" id="17229252" target="_blank">17229252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15118375">
<a name="15118375"></a>Rivarola de Gutierrez E, Abaca H. Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy. <i>Dermatology</i>. 2004;208(3):232-233. doi:10.1159/000077307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15118375/pubmed" id="15118375" target="_blank">15118375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24231065">
<a name="24231065"></a>Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. <i>Semin Arthritis Rheum</i>. 2014;43(5):613-626. doi:10.1016/j.semarthrit.2013.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/24231065/pubmed" id="24231065" target="_blank">24231065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23447478">
<a name="23447478"></a>Russo PA, Wiese MD, Smith MD, Ahern MJ, Barbara JA, Shanahan EM. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. <i>Ann Pharmacother</i>. 2013;47(3):e15. doi:10.1345/aph.1R542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/23447478/pubmed" id="23447478" target="_blank">23447478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19321513">
<a name="19321513"></a>Sawada T, Inokuma S, Sato T, et al; Study committee for leflunomide-induced lung injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2009;48(9):1069-1072. doi:10.1093/rheumatology/kep052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19321513/pubmed" id="19321513" target="_blank">19321513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19356086">
<a name="19356086"></a>Seah QM, New LS, Chan EC, Boelsterli UA. Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726. <i>Drug Metab Lett</i>. 2008;2(3):153-157. doi:10.2174/187231208785425791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19356086/pubmed" id="19356086" target="_blank">19356086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16880575">
<a name="16880575"></a>Shastri V, Betkerur J, Kushalappa PA, Savita TG, Parthasarathi G. Severe cutaneous adverse drug reaction to leflunomide: a report of five cases.<i> Indian J Dermatol Venereol Leprol</i>. 2006;72(4):286-289. doi:10.4103/0378-6323.26725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16880575/pubmed" id="16880575" target="_blank">16880575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34267852">
<a name="34267852"></a>Shields MD, Skelton WP 4th, Laber DA, Verbosky M, Ashraf N. A novel case of leflunomide-induced thrombotic thrombocytopenic purpura. <i>J Hematol</i>. 2021;10(3):139-142. doi:10.14740/jh837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/34267852/pubmed" id="34267852" target="_blank">34267852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29226391">
<a name="29226391"></a>Silva JT, Pérez-González V, Lopez-Medrano F, et al. Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. <i>Clin Transplant.</i> 2018;32(2). doi:10.1111/ctr.13176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/29226391/pubmed" id="29226391" target="_blank">29226391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15843668">
<a name="15843668"></a>Silverman E, Mouy R, Spiegel L, et al; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. <i>N Engl J Med</i>. 2005;352(16):1655-1666. doi:10.1056/NEJMoa041810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15843668/pubmed" id="15843668" target="_blank">15843668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Silverman.1">
<a name="Silverman.1"></a>Silverman E, Strand V. Leflunomide in juvenile idiopathic arthritis. <i>Future Rheumatol</i>. 2006;1(6):673-682.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545940">
<a name="26545940"></a>Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Rheumatol</i>. 2016;68(1):1-26. doi:10.1002/art.39480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/26545940/pubmed" id="26545940" target="_blank">26545940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27891379">
<a name="27891379"></a>Singh H, Sukhija G, Tanwar V, Arora S, Bhutani J. Rare occurrence of drug induced subacute cutaneous lupus erythematosus with leflunomide therapy. <i>J Clin Diagn Res</i>. 2016;10(10):OD06-OD07. doi:10.7860/JCDR/2016/14508.8667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/27891379/pubmed" id="27891379" target="_blank">27891379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9929017">
<a name="9929017"></a>Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. <i>Lancet</i>. 1999;353(9149):259-266. doi:10.1016/s0140-6736(98)09403-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/9929017/pubmed" id="9929017" target="_blank">9929017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31969328">
<a name="31969328"></a>Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Ann Rheum Dis</i>. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/31969328/pubmed" id="31969328" target="_blank">31969328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25664505">
<a name="25664505"></a>Soukup T, Dosedel M, Nekvindova J, Toms J, Vlcek J, Pavek P. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis. <i>Clin Exp Rheumatol</i>. 2015;33(3):426-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/25664505/pubmed" id="25664505" target="_blank">25664505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16120318">
<a name="16120318"></a>Spodnik JH, Wozniak M, Budzko D, et al. Mechanism of leflunomide-induced proliferation of mitochondria in mammalian cells. <i>Mitochondrion</i>. 2002;2(3):163-179. doi:10.1016/s1567-7249(02)00045-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16120318/pubmed" id="16120318" target="_blank">16120318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10573044">
<a name="10573044"></a>Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.<i> Arch Intern Med</i>. 1999;159(21):2542-50. doi:10.1001/archinte.159.21.2542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/10573044/pubmed" id="10573044" target="_blank">10573044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234643">
<a name="15234643"></a>Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. <i>Am J Med</i>. 2004;117(2):87-92. doi:10.1016/j.amjmed.2004.02.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15234643/pubmed" id="15234643" target="_blank">15234643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16645972">
<a name="16645972"></a>Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. <i>Arthritis Rheum</i>. 2006;54(5):1435-1439. doi:10.1002/art.21806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/16645972/pubmed" id="16645972" target="_blank">16645972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17041441">
<a name="17041441"></a>Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. <i>J Clin Rheumatol</i>. 2003;9(2):115-118. doi:10.1097/01.RHU.0000062514.54375.bd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/17041441/pubmed" id="17041441" target="_blank">17041441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17076730">
<a name="17076730"></a>Teraki Y, Hitomi K, Sato Y, Hamamatsu Y, Izaki S. Leflunomide-induced toxic epidermal necrolysis. <i>Int J Dermatol</i>. 2006;45(11):1370-1371. doi:10.1111/j.1365-4632.2006.03003.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/17076730/pubmed" id="17076730" target="_blank">17076730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26352135">
<a name="26352135"></a>Tidwell WJ, Malone J, Callen JP. Eruptive keratoacanthomas associated with leflunomide. <i>JAMA Dermatol</i>. 2016;152(1):105-106. doi:10.1001/jamadermatol.2015.2506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/26352135/pubmed" id="26352135" target="_blank">26352135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17929140">
<a name="17929140"></a>Toyokawa Y, Kingetsu I, Yasuda C, et al. Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. <i>Mod Rheumatol</i>. 2007;17(5):436-440. doi:10.1007/s10165-007-0613-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/17929140/pubmed" id="17929140" target="_blank">17929140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. Updated September 2016. Accessed January 4, 2024. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration, Center for Drug Evaluation and Research. Arava NDA 20905 Clinical Pharmacology and Biopharmaceutics Review(s), August 1998. Accessed May 24, 2022. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20905_ARAVA_BIOPHARMR.PDF." target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20905_ARAVA_BIOPHARMR.PDF.</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22679188">
<a name="22679188"></a>Vaish AK, Tripathi AK, Gupta LK, Jain N, Agarwal A, Verma SK. An unusual case of DRESS syndrome due to leflunomide. <i>BMJ Case Rep</i>. 2011;2011:bcr0620114330. doi:10.1136/bcr.06.2011.4330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/22679188/pubmed" id="22679188" target="_blank">22679188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15170904">
<a name="15170904"></a>van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. <i>J Rheumatol Suppl</i>. 2004;71:21-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15170904/pubmed" id="15170904" target="_blank">15170904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15061688">
<a name="15061688"></a>van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. <i>Drug Saf</i>. 2004;27(5):345-352. doi:10.2165/00002018-200427050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/15061688/pubmed" id="15061688" target="_blank">15061688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170516">
<a name="30170516"></a>Wang E, Jan AS, Doan VP, Ferguson JB, Yeh JC. Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients [published online August 31, 2018]. <i>J Oncol Pharm Pract.</i> doi:10.1177/1078155218796188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/30170516/pubmed" id="30170516" target="_blank">30170516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30720701">
<a name="30720701"></a>Wang Y, Wang F, Li H, et al. Toxic epidermal necrolysis induced by leflunomide in a patient with rheumatoid arthritis. <i>J Clin Rheumatol</i>. 2021;27(8S):S565-S567. doi:10.1097/RHU.0000000000000997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/30720701/pubmed" id="30720701" target="_blank">30720701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28478049">
<a name="28478049"></a>Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, Schaefer C. Leflunomide – A human teratogen? A still not answered question. An evaluation of the German embryotox pharmacovigilance database.<i> Reprod Toxicol.</i> 2017;71:101-107. doi:10.1016/j.reprotox.2017.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/28478049/pubmed" id="28478049" target="_blank">28478049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19080756">
<a name="19080756"></a>Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. <i>Curr Neurol Neurosci Rep</i>. 2009;9(1):69-75. doi:10.1007/s11910-009-0011-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/19080756/pubmed" id="19080756" target="_blank">19080756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11884931">
<a name="11884931"></a>Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. <i>Transplantation</i>. 2002;73(3):358-366. doi:10.1097/00007890-200202150-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/11884931/pubmed" id="11884931" target="_blank">11884931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29427785">
<a name="29427785"></a>Xuan J, Ren Z, Qing T, et al. Mitochondrial dysfunction induced by leflunomide and its active metabolite. <i>Toxicology</i>. 2018;396-397:33-45. doi:10.1016/j.tox.2018.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/29427785/pubmed" id="29427785" target="_blank">29427785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22791271">
<a name="22791271"></a>Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. <i>Mod Rheumatol</i>. 2013;23(4):709-715. doi:10.1007/s10165-012-0716-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leflunomide-pediatric-drug-information/abstract-text/22791271/pubmed" id="22791271" target="_blank">22791271</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131651 Version 94.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
